SUTRO BIOPHARMA, INC. (STRO) Total liabilities 2017–2025
SUTRO BIOPHARMA, INC. (STRO) total liabilities at each fiscal year-end, per SEC filings.
$306.3MFY2025 · since FY2017: $47.3M → $306.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $306.3M | -10.6% |
| FY2024 | $342.6M | +6.7% |
| FY2023 | $321.1M | +69.1% |
| FY2022 | $189.9M | +113.7% |
| FY2021 | $88.8M | +43.2% |
| FY2020 | $62.1M | +5.9% |
| FY2019 | $58.6M | -36.0% |
| FY2018 | $91.6M | +93.8% |
| FY2017 | $47.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More STRO financial trends
STRO RevenueSTRO Net incomeSTRO Net marginSTRO Gross profitSTRO Gross marginSTRO Operating incomeSTRO Operating marginSTRO Operating cash flowSTRO Free cash flowSTRO Capital expendituresSTRO Return on equitySTRO Stock buybacksSTRO Dividends paidSTRO Total assetsSTRO Shareholders’ equitySTRO overview →